RESEARCH ARTICLE

The unfolded protein response and its potential role in Huntington's disease elucidated by a systems biology approach [version 1; peer review: 2 approved]

Ravi Kiran Reddy Kalathur¹, Joaquin Giner-Lamia¹, Susana Machado¹, Kameshwar R S Ayasolla¹, Matthias E. Futschik^{1,2}

¹Centre for Biomedical Research, University of Algarve, Faro, 8005-139, Portugal

²Centre of Marine Sciences, University of Algarve, Faro, 8005-139, Portugal

V1 First published: 01 May 2015, 4:103
<https://doi.org/10.12688/f1000research.6358.1>

Latest published: 02 Mar 2016, 4:103
<https://doi.org/10.12688/f1000research.6358.2>

Abstract

Huntington's disease (HD) is a progressive, neurodegenerative disease with a fatal outcome. Although the disease-causing gene (huntingtin) has been known for over 20 years, the exact mechanisms leading to neuronal cell death are still controversial. One potential mechanism contributing to the massive loss of neurons observed in the brain of HD patients could be the unfolded protein response (UPR) activated by accumulation of misfolded proteins in the endoplasmic reticulum (ER). As an adaptive response to counter-balance accumulation of un- or misfolded proteins, the UPR upregulates transcription of chaperones, temporarily attenuates new translation, and activates protein degradation via the proteasome. However, persistent ER stress and an activated UPR can also cause apoptotic cell death. Although different studies have indicated a role for the UPR in HD, the evidence remains inconclusive. Here, we present extensive bioinformatic analyses that revealed UPR activation in different experimental HD models based on transcriptomic data. Accordingly, we have identified 58 genes, including RAB5A, HMGB1, CTNNB1, DNM1, TUBB, TSG101, EEF2, DYNC1H1 and SLC12A5 that provide a potential link between UPR and HD. To further elucidate the potential role of UPR as a disease-relevant process, we examined its connection to apoptosis based on molecular interaction data, and identified a set of 40 genes including ADD1, HSP90B1, IKBKB, IKBKG, RPS3A and LMNB1, which seem to be at the crossroads between these two important cellular processes.

Keywords

Unfolded protein response (UPR), Huntington's disease, Apoptosis, UPR interactome, HTT interactome

Open Peer Review

Approval Status

	1	2
version 2		
(revision)
02 Mar 2016	view

version 1
01 May 2015	view	view

1. **Scott Zeitlin**, University of Virginia, Charlottesville, USA

2. **Stefan Taubert** , University of British Columbia, Vancouver, Canada

Any reports and responses or comments on the article can be found at the end of the article.

This article is included in the **Rare diseases** collection.

Corresponding author: Matthias E. Futschik (mfutschik@ualg.pt)

Competing interests: No competing interests were disclosed.

Grant information: The work presented was supported by CHDI Foundation (A-2666) and by the Portuguese Fundação para a Ciência e a Tecnologia (SFRH/BPD/70718/2010 to RKK and IF/00881/2013 to MEF).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2015 Kalathur RKR *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Kalathur RKR, Giner-Lamia J, Machado S *et al.* **The unfolded protein response and its potential role in Huntington's disease elucidated by a systems biology approach [version 1; peer review: 2 approved]** F1000Research 2015, **4**:103 <https://doi.org/10.12688/f1000research.6358.1>

First published: 01 May 2015, **4**:103 <https://doi.org/10.12688/f1000research.6358.1>

Introduction

Huntington's disease (HD) is an autosomal-dominant neurodegenerative disorder. Its symptoms include loss of motor control, cognitive decline, and behavioural abnormalities. In most cases, the onset of the disease occurs between the age of 35 and 50. The outcome is always fatal with a life expectancy following the disease onset of around 20 years.

The treatment of HD has remained symptomatic, as currently there is still no cure. The cause of HD is a mutation in a single gene called huntingtin (*HTT*). In HD patients, an expansion of the CAG repeat in exon 1 of huntingtin has been identified¹. This mutation results in an extended stretch of polyglutamine close to the N-terminus of the Huntingtin protein (HTT), which is involved in multiple molecular functions^{2,3}. Although the molecular cause has been known now for almost 20 years, the exact mechanisms leading to the observed massive cell death of neurons in the caudate nucleus of HD patients still await full clarification. A variety of processes such as excitotoxicity^{4,5}, protein aggregation^{6–9} and transcriptional dysregulation¹⁰ have been suggested to contribute to neurodegeneration in HD. More recently, several studies have indicated that the unfolded protein response (UPR) might be implicated in neurodegenerative diseases including HD^{11–13}.

ER stress and UPR

The endoplasmic reticulum (ER) is a crucial organelle for the correct folding and modification of numerous proteins. Upon the accumulation of unfolded or misfolded protein in the ER, several transcriptional and translational mechanisms are triggered to ensure fidelity of protein folding^{14,15}. This stress response is better known as the UPR. In particular, the UPR stress sensors Inositol-requiring protein-1 (IRE1), activating transcription factor 6 (ATF-6) and PKR-like ER kinase (PERK) are activated in mammalian cells when the ER exceeds its capacity for correct folding. As an adaptive response to counter-balance accumulation of un- or misfolded proteins, the UPR (i) upregulates transcription of chaperones, (ii) temporarily attenuates new translation, and (iii) activates protein degradation via the proteasome¹⁶. The main function of the UPR is re-establishing homeostasis by increasing the overall folding capacity. Although the primary role of UPR is an adaptive one, persistent ER stress can mediate toxicity and eventually lead to apoptosis through activation of JNK, ASK1 and caspase-12. **Figure 1** depicts the different mechanisms and outcomes of UPR activation.

UPR and HD

ER stress and UPR have been indicated for a variety of neurodegenerative disorders, where protein misfolding plays a significant role^{17–19}. For HD, finding a direct connection appears to be an enigma at first glance, since HTT is not located in the ER and thus its misfolding should not trigger UPR. However, several proposals have been put forward to describe how mutant HTT (mHTT) can induce an ER stress response¹². For instance, experimental evidence from HD cell models suggests that cytosolic mHTT fragments strongly impair ER-associated protein degradation (ERAD), since mHTT entraps ERAD proteins²⁰. This impairs the proper protein catabolism, causing a potential accumulation of misfolded proteins in the ER, effectively interfering with its correct functioning. Another alternative route towards ER stress in HD could be the

Figure 1. Phases of UPR activation and putative triggering of ER stress by mHTT. One explanation for how UPR sensors IRE1, PERK and ATF6 are activated is through detachment of chaperone BiP in the presence of excess un- or misfolded protein. This leads subsequently to the execution of a series of molecular processes with different effector functions³⁶. As an adaptive response, the UPR up-regulates transcription of chaperones, temporarily attenuates new translation, and activates protein degradation via the proteasome. Persistent levels of ER stress, however, may trigger inflammatory pathways as an alarm signal in addition to caspase activation, leading ultimately to the induction of apoptosis. Mutant Huntingtin (mHTT) might provoke ER stress through interference with different processes such as vesicular transport or ER-associated degradation (ERAD) resulting in accumulation of (misfolded) protein in the ER.

perturbation of vesicular trafficking by mHTT resulting in a general protein overload in the ER or the disturbance of ER calcium homeostasis leading to a decreased folding capacity¹².

Although various lines of investigations have shown a potential role for UPR in the pathogenesis of HD, it remains difficult to assess its overall influence, given that the animal models and cell lines used in each individual study display great variability and distinct characteristics. Furthermore, most studies addressing the connection between UPR and HD focus on a small set of genes and proteins^{21,22}. As the UPR presents a potentially important process in HD progression and a novel therapeutic target, we aimed to complement these previous studies with systematic and comprehensive bioinformatic analyses. Accordingly, using a systems biology approach, we gathered all available data and focused on detecting the activation of UPR during HD, and also elucidating the potential connection between UPR and apoptosis in HD.

First, we assembled different sets of genes associated with the UPR and examined whether the included genes show differential expression in HD models or patients, when compared to controls. Next, we examined the promoter regions of upregulated UPR genes and detected significant enrichment of characteristic stress response elements. Additionally, we performed functional enrichment analysis on differentially expressed genes and found major biological processes implicated in UPR to be significantly over-represented. Furthermore, we assembled the UPR interactome and identified common proteins involved with apoptotic processes as well as with known HTT interactors, since those could provide crucial links between apoptosis and HD.

Materials and methods

Derivation of gene sets for UPR, apoptosis and HD

Since the UPR is a complex process, it is challenging to define a unique set of associated genes. Accordingly, we compiled three alternative gene sets that are either directly or indirectly involved in UPR, gathered from three distinct sources. The first termed,

UPR-KEGG-GO ($n=265$), was derived from Gene Ontology²³ (<http://geneontology.org/page/go-database>) (RRID:nif-0000-20935) and Pathway^{24,25} (<http://www.genome.jp/kegg/pathway.html>) (RRID:nlx_31015) databases indicated in Table 1. The second, referred to as UPR-interaction network ($n=281$), was generated by assembling molecular interactions of UPR components *ATF6*, *ATF4*, *DDIT3*, *EIFAK3*, *ERN1* and *XBP1* using UniHI²⁶ (<http://www.unihi.org/>) (RRID:nif-0000-03609) and HDNetDB databases (<http://hdnetdb.sysbiolab.eu>). The third gene set, labelled UPR-literature ($n=2048$) was compiled from published experimental results^{27–30} performed in yeast and human cells using high-throughput techniques such as yeast two-hybrid, microarrays and ribosome profiling coupled with next generation sequencing, as well as from text-mining of the GeneCards database³¹ (<http://www.genecards.org>) (RRID:nif-0000-02879) (Table 1).

In order to examine the genes involved in the cross-talk between UPR and apoptosis, we derived a list of genes that are either directly or indirectly involved in apoptosis from several different

Table 1. Data sources used to compile UPR gene sets.

Gene set	Sub-classification			Number of genes	Total number of unique genes
UPR-KEGG-GO	Pathway				265
	KEGG:04141: Protein processing in ER			165	
	REACTOME: Unfolded protein response			79	
	Gene ontology				
	GO:003043: ER-associated ubiquitin-dependent protein catabolic process			38	
	GO:0030968: endoplasmic reticulum unfolded protein response			89	
	GO:0034976: response to endoplasmic reticulum stress			142	
UPR-interaction Network	Interactions				281
	ATF4			92	
	ATF6			34	
	DDIT3			73	
	EIF2AK3			13	
	ERN1			37	
	XBP1			111	
UPR Literature	Publications (High through-put experiments)			1675	2048
	Study	Species	Method		
	Labunskyy VM <i>et al.</i> ²⁷	Yeast	Ribosome profiling coupled with NGS	189	
	Travers KJ <i>et al.</i> ²⁸	Yeast	DNA microarray	745	
	Jonikas MC <i>et al.</i> ²⁹	Yeast	Synthetic genetic array methodology & High-throughput flow cytometry	1262	
	Christianson JC <i>et al.</i> ³⁰	Human	Affinity purification, LC-MS/MS, High-throughput Y2H	75	
	GeneCards				
	GeneCards: ER-Stress			275	
	GeneCards: Unfolded Protein Response			325	

sources, namely the Gene Ontology database (GO:0006915; Apoptotic process; n=431), KEGG pathway (hsa04210; Apoptosis; n=88), Reactome pathway database (REACT_578.8; Apoptosis; n=148; <http://www.reactome.org/>) (RRID:nif-0000-03390) and literature reviews (n=85)^{32–36}. All genes included were annotated to be involved in the induction of apoptosis, anti-apoptosis, regulation of apoptosis or were caspases (including both activators and inhibitors).

For establishing putative links to HD, we additionally put together two other gene sets:

- (i) HD therapeutic targets (HDTT) comprising 1033 genes. This set includes genes which were annotated by the curators of the HD Research CrossRoads database as being associated with HD based on experimental evidence, making them potential therapeutic targets. A detailed description of this gene set is provided elsewhere by Kalathur *et al.*³⁷. The list of HDTT can be accessed at <http://hdttsysbiolab.eu/>.
- (ii) HTT interactors (*HTT-int*) including 1015 genes whose proteins have been shown to interact, or to be physically associated with HTT based on a diverse range of experiments. The large number of interactors can be explained through the inclusion of high-throughput affinity purification experiments, which frequently results in the addition of indirect interactions (e.g. within complexes). This set of interactors was obtained from the HDNetDB database (<http://hdnetdb.sysbiolab.eu>).

Collection and processing of HD gene expression data

All HD gene expression data used for this study were downloaded from the Gene Expression Omnibus (GEO) database³⁸ (<http://www.ncbi.nlm.nih.gov/geo/>) (RRID:nif-0000-00142). These data include gene expression from human brain and blood samples, human iPSCs, mouse, rat and yeast HD models, as well as murine cell lines (Table 2). All expression data sets were pre-processed using RMA (Robust Multi-array Average) implemented in R (available at <http://www.r-project.org/>) (RRID:nif-0000-10474) and analysed

using several Bioconductor packages^{39,40} (RRID:nif-0000-10445). To enable the comparison across organisms, we mapped genes from mouse, rat, worm and yeast to orthologous human genes using HGNC Comparison of Orthology Predictions (HCOP) search tool (available online at <http://www.genenames.org/cgi-bin/hcop>), which is based on integrated data from HUGO Gene Nomenclature Committee (HGNC)⁴¹ (RRID:nif-0000-02955).

Identification of differential expression using Gene Set Enrichment Analysis (GSEA)

We performed gene set enrichment analysis (GSEA)⁴² (RRID:nif-0000-30629) comparing HD-associated expression to wild type or control data to identify differentially expressed genes. As input, we used the above-mentioned UPR gene sets and HD gene expression data. UPR genes were identified as significant when the enrichment score (ES) corresponded to a false discovery rate (fdr) ≤ 0.05 in HD gene expression data sets. For further analysis, we used only the genes present in the 'UPR core enrichment' gene sets. Those genes belonged to the leading-edge subsets and contributed the most to the enrichment scores, and are the most differentially expressed among the UPR genes. To visualize these results, we generated Venn diagrams using *jvenn*⁴³, to display the common genes across alternative comparisons.

Identification of stress response elements in the promoter regions

In order to verify the presence of unfolded protein response element (UPRE) and ER stress response elements (ERSE I and II)⁴⁴ in the upstream regions (-1000bp to +500bp) of UPR genes upregulated in HD, we downloaded all the human promoter regions, (n=23322) available in the eukaryotic promoter database (EDP; <http://epd.vital-it.ch>)⁴⁵ (RRID:nif-0000-02806). Next, we used Regulatory Sequence Analysis Tools (RSAT)⁴⁶ to map these elements in the promoters and computed the enrichment of these stress elements in promoters of upregulated UPR genes compared to all the human promoters using hypergeometric test (equivalent to Fisher's exact test).

Table 2. List of HD gene expression datasets used for the gene set enrichment analysis.

GEO ID	Sample	Organism	Pubmed id
GSE3790	HD (CN) vs Control	Human	16467349
GSE24250	HD vs Control (blood)	Human	21969577
GSE37547	HD-iPSc vs corrected HD iPSc	Human	22748967
GSE3621	R6/1-18w, 22w, 27w vs WT	Mouse	17696994
GSE9803	R6/2-12w vs WT	Mouse	17519223
GSE10202	CHL2-22m vs WT	Mouse	17519223
GSE9330	Ctip2-KO vs WT	Mouse	18199763
GSE18551	YAC128-12, 24m vs WT	Mouse	20089533
GSE3583	HdhQ111 vs WT	Mouse	17708681
GSE9760	mESC (CAG150)-d4, d6 vs WT	Mouse	NA
GSE12481	Neuronal-culture 82Q vs CT	Rat	18815258
GSE18644	Htt103Q vs Htt25Q	Yeast	21044956

Functional enrichment analysis

To identify enriched biological processes in our gene sets we used BiNGO⁴⁷ (RRID:nlx_149196) for Cytoscape⁴⁸ (<http://apps.cytoscape.org/apps/bingo>) (RRID:nif-0000-30404); and GSEA⁴² (RRID:nif-0000-30629) to evaluate if genes from curated Reactome pathways (obtained from the Molecular Signature Database (MsigDB)⁴⁹) were statistically over-represented. The significance of each identified biological process or pathway was calculated using the hypergeometric test, adjusted for multiple testing and converted to *fdr*s using the Benjamini and Hochberg method⁵⁰ implemented in BiNGO (RRID:nlx_149196) or in GSEA (RRID:nif-0000-30629), respectively. We considered only those processes and pathways with an *fdr* of ≤ 0.05 to be significantly enriched.

Results and discussion

Identification of common UPR genes across HD gene expression studies

To determine possible implications of the UPR in HD, we sought to assess its activation using a computational approach and the evaluation of existing data. First, we catalogued genes that are involved in UPR from several different sources and divided them into three different categories: UPR-KEGG-GO, UPR-interactions and UPR-literature as described in Material and Methods section and detailed in Table 1 and Supplementary Figure 1.

Since changes in gene transcription are main effects of UPR activation and published microarray data are available for HD in humans as well as for HD models, we collected 12 different gene expression datasets generated for the study of HD: three datasets included expression from human blood and brain samples as well as human induced pluripotent stem cells (iPSCs); seven datasets were derived from HD mouse models and cell cultures; one from rat cells and one from yeast cells. If the expression dataset constituted time-series, we split the dataset according to the time points to maintain the temporal aspect of the expression changes.

We reasoned that UPR activity should be reflected in the regulation of UPR genes. By applying GSEA we tested whether UPR genes tend to be differentially expressed in HD samples or models compared to the corresponding controls. GSEA was employed, since it is able to detect modest but consistent tendencies in expression change within a pre-defined set of genes. This can be seen as a crucial advantage, as only small changes in gene expression are frequently observed in the study of neurodegenerative disease due to heterogeneity of tissue samples and biological variability of the underlying processes.

Remarkably, we found both indications for significant upregulation as well as repression of UPR genes in the different comparisons. Notably, significant differential expression was generally consistent across the three alternative UPR gene sets (with the exception of R6/1 mice at 27 weeks, where UPR-Literature genes tended to be downregulated while UPR-GO-KEGG genes displayed upregulation) (Figure 2). This observation implies that the obtained findings tend to be independent of the particular definition of UPR genes chosen in this study.

For most murine *in vivo* HD models, a significant upregulation was detected. Interestingly, the activation pattern was dependent on the time point of expression measurement for the two mouse models (R6/1 and YAC128), for which time series data were available. In the case of R6/1 mice, expressing exon 1 of the human *HTT* gene with a 115 CAG repeat, the most significant activation of UPR genes occurs after 18 and 22 weeks, while genes included in UPR-Literature and UPR-interactions sets tend to be downregulated after 27 weeks. In contrast, upregulation of UPR genes is only observed at the later time point (24 months), whereas downregulation dominates after 12 months for YAC128 mice containing the full length human *HTT* gene with 128 CAG repeats. This divergence may be explained by the rapid development of an aggressive disease phenotype in R6/1 mice compared to YAC128 mice, which show a milder phenotype with slower progression (Figure 2).

Inspecting the three human expression datasets, only the iPSC HD model showed a highly significant activation for all three UPR gene sets, whereas no consistent differential expression of the three UPR gene sets could be detected in blood and brain samples of HD patients. For whole blood samples, this observation might not be surprising, since erythrocytes - constituting the main component of blood - lack of an ER. The absence of a clear pattern in HD brain expression might be due to the fact that expression data were obtained from the post-mortem samples and thus represent typically only the very late stage of the disease. Finally, no significant alterations of expression was found for the rat *in vitro* and the yeast HD model (Figure 2).

Next, we sought to identify UPR genes which showed conserved differential regulation in distinct HD models. For this purpose, we collected genes that were assigned to the enrichment core by GSEA in the comparisons that showed significant upregulation of UPR genes. In total we collected the UPR genes contained in the enrichment cores from five mouse HD models and the human HD iPSC model. Intersection of these sets led to the identification of 132 genes

Species	Human	Human	Human	Mouse	Mouse	Mouse	Mouse	Mouse	Mouse	Mouse	Mouse	Mouse	Mouse	Mouse	Mouse	Rat	Yeast
Model	HD_CN	HD_blood	HD_iPSc	R6/1_18W	R6/1_22W	R6/1_27W	R6/2_12W	CHL2_22M	Ctip2-/-	YAC128_12M	YAC128_24M	HdhQ111	CAG150_D4	CAG150_D6		82Q	4 mut
Gene Set	GEO	GSE3790	GSE24250	GSE37547	GSE3621	GSE3621	GSE3621	GSE9803	GSE10202	GSE9330	GSE18551	GSE18551	GSE3583	GSE9760	GSE9760	GSE12481	GSE18644
UPR-LIT		-2.61	-2.03	5.06	3.05	3.12	-3.09	2.77	3.33	7.23	-2.17	3.58	1.98	-2.5	-2.95	-1.06	-1.35
UPR-GO-KEGG		1.51	-0.92	3.25	2.09	2.23	1.69	2.24	2.86	3.47	-1.65	2.55	1.82	-2.45	-2.48	-1.14	0.99
UPR-Interactions		0.8	0.79	3.08	1.86	1.46	-1.32	1.45	1.82	3.1	0.7	1.67	1.59	-2.6	-2.23	1.19	NA

Figure 2. Differential regulation of UPR gene sets detected in HD expression data. For each of the compiled UPR genes sets, the normalized enrichment scores (NES) produced by GSEA are shown for different comparisons of HD-associated expression with controls. Positive scores indicate a tendency towards upregulation; negatives scores indicate a tendency towards downregulation of genes in the UPR sets. Comparisons that showed significant upregulation of UPR gene sets (*fdr* ≤ 0.05 and $NES \geq +1.4$) are highlighted by red background, while significant downregulation (*fdr* ≤ 0.05 and $NES \leq -1.4$) by green background.

that were commonly upregulated, when UPR activation was indicated (Figure 3, Supplementary data file 1). We refer to this set of genes as *UPR-HD^{up}*. As UPR has been also associated with the suppression or degradation of a substantial number of genes^{51,52}, we carried out the equivalent procedure to identify UPR genes whose downregulation is conserved in different HD models. Here, we intersected the enrichments core from comparisons displaying suppression of UPR genes (Supplementary Figure 2, Supplementary data file 2). This resulted in 81 commonly downregulated genes. We refer to the combined set of UPR genes (consisting of 132 upregulated and 81 downregulated genes) that were commonly detected as differentially regulated in HD gene expression data as *UPR-HD^{diff}*.

Examining stress response elements in the promoter regions of upregulated UPR genes

To assess whether the observed upregulation indeed reflects the activation of UPR or if it might be a consequence of other unrelated processes, we carried out an analysis of the promoter regions of genes included in *UPR-HD^{up}*. We searched for the presence of sequence elements that indicate binding of transcription factors associated with the UPR. In particular, we searched for unfolded protein response elements (UPRE; TGACGTG (G/A)) and the alternative

ER stress response elements I (ERSE I; CCAAT(N9)CCACG) and II (ERSE II; ATTGG-N-CCACG) in promoter regions (-1000 bp to +500 bp) regions of *UPR-HD^{up}* genes. These characteristic sequence elements are targeted by the bZIP transcription factors ATF6 and XBP1, which are main mediators of the transcriptional adaptation evoked by UPR⁵³.

Strikingly, we found that the vast majority of the *UPR-HD^{up}* has such a characteristic binding sequence in their promoter regions (Supplementary Figure 3). Compared to number of sequence elements that we would expect by chance, a highly significant overrepresentation was detected for the *UPR-HD^{up}* genes. More specifically, we found the occurrence of UPRE in 104 genes ($p=3.0 \cdot 10^{-9}$), ERSE-I in 93 genes ($p=0.0019$), and ERSE-II in 8 ($p=0.052$). Notably, a large number of *UPR-HD^{up}* genes had alternative binding motifs included in the promoter region: 70 genes had both ERSE-I and UPRE, 2 genes had both ERSE-I and ERSE-II and six genes had all three elements (for list of genes see Supplementary data file 3) which might suggest that these genes are under particularly tight control of UPR-associated transcription factors ATF6 and XBP1. Altogether, the results of the promoter analysis support the conclusion that the upregulation of UPR genes in HD models faithfully reflects an activated UPR.

Figure 3. Up regulated UPR genes. Genes included in the core enrichment set for comparisons that indicated UPR activation (highlighted in red in Figure 2) were compared. Common upregulated UPR genes (n=169) in five HD mouse models (left side) were intersected with upregulated UPR genes in human HD iPSCs (right side) resulting in a set of 132 UPR genes, whose activation was conserved across the different HD models. The bar plots (bottom) display the number of UPR genes that were assigned to the core enrichment sets for comparisons that indicated upregulation.

Biological processes that are enriched in differentially expressed UPR genes

Since the UPR comprises a complex series of diverse molecular mechanisms, we examined the functional composition of UPR- HD^{diff} genes. For this purpose, we performed functional analysis using BiNGO to identify enriched biological processes (as defined in GO) that are overrepresented among UPR- HD^{diff} genes. All the biological processes that are significantly enriched in our analysis are listed in [Supplementary data file 4](#). Expectedly, we detected that stress-related functional categories such as ‘response to stress’ (GO ID:6950; $n=44$; $fdr=2.08\text{E-}03$) and ‘response to unfolded protein’ (GO ID:6986; $n=13$; $fdr=4.55\text{E-}09$) were enriched ([Figure 4a](#)). A second group of significantly overrepresented GO categories were related to ‘protein transport’ (GO ID:15031; $n=34$; $fdr=1.76\text{E-}07$) and ‘protein localization’ (GO ID:8104; $n=36$; $fdr=1.19\text{E-}06$) including ‘vesicle-mediated transport’ (GO ID:16192; $n=24$; $fdr=9.03\text{E-}05$) and ‘ER to Golgi vesicle-mediated transport’ (GO ID:6888; $n=4$; $fdr=4.00\text{E-}02$) ([Figure 4b](#)). Additionally, we also found ‘ER-nucleus signalling pathway’ (GO ID:6984; $n=9$; $\text{adj-p-value}=1.81\text{E-}07$) to be highly enriched. It has been previously reported that ER-nucleus signalling pathway functions via activation of NF- κB due to ER-overload triggered by protein congestion⁵⁴.

Furthermore, UPR- HD^{diff} genes tended to be associated with protein catabolism and in particular protein degradation ([Figure 4c](#)). Significant processes here were e.g. ‘protein catabolic process’ (GO ID:30163; $n=18$; $fdr=6.40\text{E-}05$), ‘proteasomal ubiquitin-dependent protein catabolic process’ (GO ID:43161; $n=13$; $fdr=6.69\text{E-}06$) and ‘protein ubiquitination’ (GO ID:31396; $n=7$; $fdr=3.12\text{E-}02$). These results coincide well with previous studies establishing the connection of UPR and ERAD and showing, for instance, that the extent of activation of the UPR is concurrent with the severity of ERAD defect⁵⁵.

Finally, genes linked to apoptosis could be found among the UPR- HD^{diff} genes ([Figure 4d](#)). Of particular interest for potential intervention could be genes associated with ‘regulation of apoptosis’ (GO ID:42981; $n=24$; $fdr=1.65\text{E-}02$), as their manipulation may prevent the execution of the apoptotic programme under persistent ER stress.

In summary, UPR genes detected as commonly differentially regulated in HD expression data were not restricted to a particular functional category, but can be associated with many processes linked to the UPR.

Pathways enriched in upregulated genes

Complementary to the functional composition, we evaluated whether specific pathways might be activated based on the observed commonly upregulated UPR genes (UPR- HD^{up}). Therefore, we carried out pathway enrichment analysis using a set of pathways curated in the Reactome database. As expected, ‘unfolded protein response’ ($n=6$; $fdr=2.04\text{E-}05$), ‘activation of genes by ATF4’ ($n=3$; $fdr=0.00291$) and ‘PERK regulated gene expression’ ($n=3$; $fdr=0.0033$) were detected as significantly enriched among UPR- HD^{up} genes ([Figure 5](#)). More interestingly, we also found an overrepresentation of components of the ‘immune system’ ($n=14$;

$fdr=6.74\text{E-}05$), ‘adaptive immune system’ ($n=6$; $fdr=1.96\text{E-}03$), ‘NGF signalling’ ($n=9$; $fdr=2.42\text{E-}03$), and ‘Diabetes pathways’ ($n=7$; $fdr=2.04\text{E-}05$). Complete results from the analysis are included in [Supplementary data file 5](#).

Remarkably, recent studies have also suggested that ER stress and activated UPR are interconnected with inflammatory processes⁵⁶. Inflammation is an immunological process usually carried out by the vascular system to counteract disease, and to fight foreign antigens against invasion. Within the brain, microglia and astrocytes play important immunological functions. Until very recently, little was known about inflammatory molecules in HD. Recent studies, however revealed a distinct profile of inflammatory mediators from post-mortem human HD tissue^{57,58}. Inflammatory mediators such as IL-1 β and TNF- α were increased only in the striatum, whereas IL-6, IL-8 and MMP-9 were also upregulated in cortex and in the cerebellum⁵⁸. This supports the conjecture that secreted inflammatory cytokines and activated microglia cells could lead to axonal damage and extensive neuronal cell death in HD pathology⁵⁷⁻⁶⁰. In general, activated microglia exert their diverse effects on neurons and macroglia (astrocytes and oligodendrocytes). Inflammation occurs through the release of cytoprotective agents such as growth factors, plasminogen, and neuroprotective cytokine as well as cytotoxic substances such as oxygen radicals, nitric oxide, glutamate, proteases, and neurotoxic cytokines. One of the earliest reports describing microglial abnormalities in HD was provided by Singhrao *et al.*⁶⁰. Microglial cell counts were considerably increased in the caudate putamen of HD and these microglial cells expressed increased amounts of complement factors. A more detailed investigation of microglial morphological changes associated with HD was performed by Sapp *et al.*⁶¹. The authors localized morphologically activated microglial cells in the neostriatum, cortex and globus pallidus as well as in adjoining white matter of HD brains. Additionally, positron emission tomography (PET) studies using the ligand for benzodiazepine receptor (PK-11195), which labels activated microglia have been employed to study of neuroinflammation. Using this technique, Tai *et al.*^{62,63} demonstrated that microglial activation in HD patients correlates with disease progression as assessed by loss of dopamine D2 receptor binding sites. Interestingly, Tai *et al.* could also demonstrate that microglial activation and release of cytokine IL-6 is observed in presymptomatic HD gene carriers and can be detected up to 15 years before predicted age of onset. These findings indicate the microglial inflammatory activation is an early event associated with subclinical progression of HD and may constitute a target for early therapeutic intervention.

Besides the indication of processes related to the immune response, results of the pathway enrichment analysis also pointed to diabetes. It has been shown that diabetes in Wolcott-Rallison syndrome (a rare autosomal recessive form of juvenile diabetes) is a result of high levels of ER stress caused by mutations in the PERK gene in pancreatic β -cells. In addition, studies have shown that HD patients show increased incidence of diabetes^{64,65} and HD transgenic mice develop hyperglycemia^{66,67}. More recently it has been experimentally validated that HD transgenic mice develop intranuclear inclusions in the pancreatic β -cells, causing an intrinsic defect in insulin production⁶⁸.

Figure 5. Pathways enriched among upregulated UPR genes. The network of pathways with overrepresentation of upregulated UPR genes are shown. Node size represents number of genes in each pathway and connecting line size represents number of genes shared between two pathways. Colour coding from white to red indicates increasing statistical significance. Pathways were derived from the Reactome database.

Prioritization of UPR-HD connectors through integrative analysis

To narrow down the list of UPR-HD^{diff} genes for further inspection, we utilized additional information, including a reference set of potential molecular targets for HD therapy that were made available through the HD Research Crossroads database initiated by the CHDI Foundation (see Kalathur *et al.* 2012)³⁷. Genes were included by experts in the field based on the evaluation of published literature and in-house screens using a set of defined criteria (see Kalathur *et al.* 2012)³⁷. For instance, a gene was considered as a potential HDTT if genetic or pharmacologic modification of its activity led to a change of a HD-related phenotype in a validated cell culture or organism model of HD. At present, this curated reference set constitutes the most comprehensive collection of HDTTs. In addition, we extracted genes, whose corresponding proteins were reported to be physically associated with HTT, from the HDNetDB database. We recently demonstrated that HTT interactors tend to be enriched in proteins that influence the toxicity of mHTT, and provide favourable candidates for the identification of molecular modifiers of HD⁶⁹.

We reasoned that differentially regulated UPR genes, which have been shown to influence HD-related phenotypes and to be physically associated with HTT, could constitute molecular links between UPR and HD. Therefore, we integrated the three gene lists and identified 13 genes that were common to all three: *RAB5A*, *HMGB1*, *CTNNA1*, *DNM1*, *TCP1*, *TUBB*, *TSG101*, *DNAJB1*, *CCT2*, *EEF2*, *DYNC1H1*, *HSPA5* and *SLC12A5* (Supplementary Figure 4).

Notably, the search for stress response elements in the upstream regions of these 13 genes revealed that eight genes (*RAB5A*, *HMGB1*, *CTNNA1*, *DNM1*, *TCP1*, *TUBB*, *TSG101* and *DNAJB1*) possess either UPRE or ERSE or both elements in their promoters, suggesting that these genes are under direct control of UPR-associated transcription factors (Table 3).

Inspection of the genes possessing UPRE or ERSE elements in their promoter regions revealed that four of them (*TCP1*, *CCT2*, *DNAJB1* and *HMGB1*) have been reported to act as chaperones. Besides being essential components of the UPR, molecular chaperones can modulate the aggregation and toxicity of proteins, including mHTT. *TCP1* (*CCT1*) and *CCT2* are components of the *TCP1* ring complex (*TRiC*) that uses cycles of ATP-binding and hydrolysis to bind unfolded polypeptides and facilitate their folding. Notably, *TRiC* has been identified as a potent suppressor of mHTT mediated toxicity and inhibitor of the mHTT protein aggregation *in vitro* and *in vivo*⁷⁰. *DNAJB1* belongs to the group of DnaJ/Hsp40 (Heat shock protein 40) proteins that are involved in protein translation, folding and translocation through regulating ATPase activity of the Hsp70s chaperones. In a PC12 cell model, experiments indicated that *DNAJB1* attaches to soluble mHTT oligomers and recruits Hsp70 suppressing mHTT mediated toxicity⁷¹. Finally, *HMGB1* encodes for the High-mobility group box 1 protein (HMGB1), which has recently been demonstrated to have chaperone-like activity, inhibiting aggregation of various proteins. Overexpression of HMGB1 can also decrease the aggregation induced by extended polyQ stretches⁷².

Table 3. Presence of ER stress-associated sequence motifs in the promoter regions of differentially regulated UPR genes that interact with HTT and were classified as potential HD therapeutic targets (HDTT).
+ indicates the presence of particular stress response element in the promoter regions (+1000 to -500 bp).

Gene	UPRE	ERSE-I	ERSE-II
RAB5A	+	+	
HMGB1	+	+	
CTNNB1		+	
DNM1	+	+	
TCP1	+	+	
TUBB	+	+	
TSG101	+	+	
DNAJB1	+		+
CCT2			
EEF2			
DYNC1H1			
HSPA5			
SLC12A5			

Linking the UPR network to apoptosis and HTT

A crucial aspect of the UPR in the context of HD is the possibility that it can trigger apoptosis upon persistent ER stress. To obtain a comprehensive view of the connections between UPR and apoptosis, we applied a network approach. First, we generated the UPR interactome from known protein interactions of UPR core components, which we extracted from the UniHI and HDNetDB databases (Supplementary data file 6). Second, we compiled a list of genes (n=594) associated with apoptosis from several different sources (as described in the materials and methods). We then used this list to identify 40 proteins associated with apoptosis within the UPR interactome (Supplementary data file 7). These genes included, among others, Apoptosis Signal Regulating Kinase 1 (ASK1, also known as MAP3K5), whose knock-out in primary neuron provided protection from ER stress-induced JNK activation and cell death triggered by polyQ fragments⁷³.

As the mutation in HTT can perturb the function of interacting proteins by aberrant binding, we checked for each of the 40 proteins whether they have been reported to physically associate with HTT. Using molecular interaction data collected in HDNetDB, we detected that six of the 40 proteins interact with HTT i.e. ADD1, HSP90B1, IKBKB, RPS3A, IKBKG and LMNB1 (Supplementary data file 7). A visualisation of the UPR interactome with apoptosis-related proteins and HTT interactors highlighted can be found in Figure 6.

Literature review showed that the two proteins kinases IKBKB and IKBKG, the laminin LMNB1 and the ribosomal protein RPS3A have been previously linked to neurodegenerative diseases. IKBKB and IKBKG are subunits of I κ B kinase (IKK). They activate members of the NF- κ B transcription factor family by phosphorylation of their inhibitor (I κ B)⁷⁴ leading to ubiquitination and destruction of I κ B, thereby allowing activation of the NF- κ B complex. NF- κ B maintains the balance between cell survival and apoptosis⁷⁵. Although

unrelated to ER stress, it has been shown that inhibition of IKBKB decreases HTT proteolysis in a cell model, and thus might lower the load of toxic HTT fragments in HD⁷⁶. Recently, it has been reported that ubiquitination of IKBKG by Parkin, an ubiquitin ligase associated with Parkinson's disease regulates the anti-apoptotic pathway that is key to maintaining mitochondrial integrity⁷⁷.

Lamin B1 protein, LMNB1 is thought to be involved in nuclear stability and chromatin structure. Experiments in *Caenorhabditis elegans* overexpressing aggregation-prone peptides identified laminins as modulators of protein toxicity at neuromuscular junctions⁷⁸. Further, in leukodystrophy mouse models, lamin B1 acts as an important regulator of myelin formation and maintenance⁷⁹, in humans lamin B1 gene duplications⁸⁰ and large deletions upstream of promoter regions can cause autosomal-dominant leukodystrophy⁸¹. More importantly, a recent study reports increased levels of lamin B1 in both human HD patients and the R6/1 mouse model of HD⁸². Due to the involvement of lamin B1 in several cellular alterations such as chromatin organisation, gene transcription and proteotoxicity, alterations in lamin B1 expression might have important implications in HD pathophysiology.

Finally, it has been demonstrated that apoptosis is induced by inhibiting the expression of ribosomal protein S3A (RPS3A)⁸³. It also has been observed that SNP variants in RPS3A homologues are associated with pathogenesis of Alzheimer's disease⁸⁴. Apart from its function as a ribosomal protein, RPS3A might also act as a chaperone. Co-expression of mouse RPS3A suppressed the toxicity induced by α -synuclein (which is a major components of Lewy bodies observed in Parkinson's disease) in a yeast model system⁸⁵.

As the literature review indicated, the intersection of the UPR interactome with apoptosis-related genes and HTT interactors can point out proteins with potential relevance for neurodegeneration. Thus, the generated gene lists provided in the Supplementary data file 6 and Supplementary data file 7 might give interested researchers a valuable basis for more detailed inspections.

Raw data for Kalathur *et al.*, 2015 'The unfolded protein response and its potential role in Huntington's disease elucidated by a systems biology approach'

7 Data Files

<http://dx.doi.org/10.6084/m9.figshare.1383080>

Conclusions

Various studies have indicated a role of the UPR in HD. However, its relevance for therapeutic interventions remains to be established. With the presented work, we aimed to delineate the connection between UPR and HD by examining available HD-relevant gene expression and molecular interaction data. We found indications for differential regulation of UPR genes in a number of expression studies. Notably, the observed differential regulation is not conserved across all evaluated studies reflecting the well-known heterogeneity of current HD models. This needs to be taken into account for future studies of the UPR in the context of HD. The results of our analysis (displayed in Figure 2) may therefore serve as guidance

Functional enrichment analysis on differentially expressed UPR genes pointed to a broad range of mechanisms involved. Additional pathway analyses indicated the activation of inflammatory processes and a potential connection to diabetes. Including complementary data sets, we identified UPR genes that have been indicated to influence HD pathogenesis. Finally, we derived sets of genes that connect UPR with apoptosis and might be directly influenced by mHTT.

In summary, through our work we present the first comprehensive analysis of UPR activation in HD and elucidate potential links to pathogenetic mechanisms within a systems biology framework. While our work cannot provide definite proofs for the identified relations due to its purely computational nature, it can nevertheless constitute a broad basis for experimental follow-up investigations. To assist such endeavours, extensive supplementary material has been provided together with this article with the aim of helping independent researchers to select genes of interest. We are also currently developing a publicly accessible web-portal for the retrieval and visualisation of changes in UPR-associated gene expression across the evaluated transcriptomics studies. In conclusion, we hope that our work can contribute to a better understanding of the UPR in HD and eventually to the identification of novel therapeutic targets to cure HD.

Data availability

Figshare: Raw data for Kalathur *et al.*, 2015 ‘The unfolded protein response and its potential role in Huntington’s disease elucidated by a systems biology approach’ doi: [10.6084/m9.figshare.1383080](https://doi.org/10.6084/m9.figshare.1383080)⁸⁷

Supplementary information

Supplementary Figure 1. Comparison of UPR gene lists. Venn diagram comparing the three different UPR genes lists generated.

Author contributions

RK collected the data, performed the analysis and prepared manuscript. JGL, SM and KA collected data and wrote parts of manuscript. MF conceived the study, contributed to interpretation of the results and wrote the final version of the manuscript. All authors agreed to the final content of the manuscript.

Competing interests

No competing interests were disclosed.

Grant information

The work presented was supported by CHDI Foundation (A-2666) and by the Portuguese Fundação para a Ciência e a Tecnologia (SFRH/BPD/70718/2010 to RKK and IF/00881/2013 to MEF).

Acknowledgements

We would like to thank Isabel Duarte for critical reading of the manuscript.

Supplementary Figure 2. Common downregulated UPR genes. Comparison of several HD expression data sets to identify UPR genes that are downregulated in different HD models.

Supplementary Figure 3. Comparison of UPRE and ERSE elements in the promoter region of UPR genes that are upregulated in HD.

Supplementary Figure 4. UPR-HD connectors. Venn diagram showing common genes between 3 data sets, UPR-HDdiff: UPR genes that are differentially regulated in HD; HDTT: HD therapeutic targets as described by Kalathur RK *et al.*³⁷ and originated by the HDCrossRoads database; and HTT-int: HTT interactors derived from the HDNetDB.

References

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. *Cell*. 1993; 72(6): 971–83. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Cattaneo E, Zuccato C, Tartari M: Normal huntingtin function: an alternative approach to Huntington's disease. *Nat Rev Neurosci*. 2005; 6(12): 919–30. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Li SH, Li XJ: Huntingtin-protein interactions and the pathogenesis of Huntington's disease. *Trends Genet*. 2004; 20(3): 146–54. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Raymond LA, Andre VM, Cepeda C, *et al.*: Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. *Neuroscience*. 2011; 198: 252–73. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Beal MF, Kowall NW, Ellison DW, *et al.*: Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. *Nature*. 1986; 321(6066): 168–71. [PubMed Abstract](#) | [Publisher Full Text](#)
6. Arrasate M, Finkbeiner S: Protein aggregates in Huntington's disease. *Exp Neurol*. 2012; 238(1): 1–11. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Becher MW, Kotzok JA, Sharp AH, *et al.*: Intracellular neuronal inclusions in Huntington's disease and dentatorubral and pallidolysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. *Neurobiol Dis*. 1998; 4(6): 387–97. [PubMed Abstract](#) | [Publisher Full Text](#)
8. DiFiglia M, Sapp E, Chase KO, *et al.*: Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. *Science*. 1997; 277(5334): 1990–3. [PubMed Abstract](#) | [Publisher Full Text](#)
9. Gutekunst CA, Li SH, Yi H, *et al.*: Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. *J Neurosci*. 1999; 19(7): 2522–34. [PubMed Abstract](#)
10. Sugars KL, Rubinsztein DC: Transcriptional abnormalities in Huntington disease. *Trends Genet*. 2003; 19(5): 233–8. [PubMed Abstract](#) | [Publisher Full Text](#)
11. Forman MS, Lee VM, Trojanowski JQ: 'Unfolding' pathways in neurodegenerative disease. *Trends Neurosci*. 2003; 26(8): 407–10. [PubMed Abstract](#) | [Publisher Full Text](#)
12. Vidal R, Caballero B, Couve A, *et al.*: Converging pathways in the occurrence of endoplasmic reticulum (ER) stress in Huntington's disease. *Curr Mol Med*. 2011; 11(1): 1–12. [PubMed Abstract](#) | [Publisher Full Text](#)

13. Matus S, Glimcher LH, Hetz C: **Protein folding stress in neurodegenerative diseases: a glimpse into the ER.** *Curr Opin Cell Biol.* 2011; **23**(2): 239–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Rutkowski DT, Kaufman RJ: **That which does not kill me makes me stronger: adapting to chronic ER stress.** *Trends Biochem Sci.* 2007; **32**(10): 469–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Bernales S, McDonald KL, Walter P: **Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response.** *PLoS Biol.* 2006; **4**(12): e423.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Matus S, Lisbona F, Torres M, *et al.*: **The stress rheostat: an interplay between the unfolded protein response (UPR) and autophagy in neurodegeneration.** *Curr Mol Med.* 2008; **8**(3): 157–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Sherman MY, Goldberg AL: **Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases.** *Neuron.* 2001; **29**(1): 15–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Alves-Rodrigues A, Gregori L, Figueiredo-Pereira ME: **Ubiquitin, cellular inclusions and their role in neurodegeneration.** *Trends Neurosci.* 1998; **21**(12): 516–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Soto C: **Unfolding the role of protein misfolding in neurodegenerative diseases.** *Nat Rev Neurosci.* 2003; **4**(1): 49–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Duenwald ML, Lindquist S: **Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity.** *Genes Dev.* 2008; **22**(23): 3308–19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Vidal RL, Figueroa A, Court FA, *et al.*: **Targeting the UPR transcription factor XBP₁ protects against Huntington's disease through the regulation of FoxO1 and autophagy.** *Hum Mol Genet.* 2012; **21**(10): 2245–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Lajoie P, Snapp EL: **Changes in BIP availability reveal hypersensitivity to acute endoplasmic reticulum stress in cells expressing mutant huntingtin.** *J Cell Sci.* 2011; **124**(Pt 19): 3332–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Ashburner M, Ball CA, Blake JA, *et al.*: **Gene ontology: tool for the unification of biology. The Gene Ontology Consortium.** *Nat Genet.* 2000; **25**(1): 25–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Croft D, Mundo AF, Haw R, *et al.*: **The Reactome pathway knowledgebase.** *Nucleic Acids Res.* 2014; **42**(Database issue): D472–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Kanehisa M, Goto S, Sato Y, *et al.*: **Data, information, knowledge and principle: back to metabolism in KEGG.** *Nucleic Acids Res.* 2014; **42**(Database issue): D199–205.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Kalathur RK, Pinto JP, Hernandez-Prieto MA, *et al.*: **UniHI: an enhanced database for retrieval and interactive analysis of human molecular interaction networks.** *Nucleic Acids Res.* 2014; **42**(Database issue): D408–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Labunskyy VM, Gerashchenko MV, Delaney JR, *et al.*: **Lifespan extension conferred by endoplasmic reticulum secretory pathway deficiency requires induction of the unfolded protein response.** *PLoS Genet.* 2014; **10**(1): e1004019.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Travers KJ, Patil CK, Wodicka L, *et al.*: **Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation.** *Cell.* 2000; **101**(3): 249–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Jonikas MC, Collins SR, Denic V, *et al.*: **Comprehensive characterization of genes required for protein folding in the endoplasmic reticulum.** *Science.* 2009; **323**(5922): 1693–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Christianson JC, Olzmann JA, Shaler TA, *et al.*: **Defining human ERAD networks through an integrative mapping strategy.** *Nat Cell Biol.* 2012; **14**(1): 93–105.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Safran M, Dalah I, Alexander J, *et al.*: **GeneCards Version 3: the human gene integrator.** *Database (Oxford).* 2010; **2010**: baq020.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Portt L, Norman G, Clapp C, *et al.*: **Anti-apoptosis and cell survival: a review.** *Biochim Biophys Acta.* 2011; **1813**(1): 238–59.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Bursch W, Ellinger A, Gerner C, *et al.*: **Programmed cell death (PCD). Apoptosis, autophagic PCD, or others?** *Ann NY Acad Sci.* 2000; **926**: 1–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Blomgren K, Leist M, Groc L: **Pathological apoptosis in the developing brain.** *Apoptosis.* 2007; **12**(5): 993–1010.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Ouyang L, Shi Z, Zhao S, *et al.*: **Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis.** *Cell Prolif.* 2012; **45**(6): 487–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Bredesen DE: **Programmed cell death mechanisms in neurological disease.** *Curr Mol Med.* 2008; **8**(3): 173–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Kalathur RK, Hernandez-Prieto MA, Futschik ME: **Huntington's disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads database.** *BMC Neurol.* 2012; **12**: 47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Barrett T, Wilhite SE, Ledoux P, *et al.*: **NCBI GEO: archive for functional genomics data sets—update.** *Nucleic Acids Res.* 2013; **41**(Database issue): D991–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Gentleman RC, Carey VJ, Bates DM, *et al.*: **Bioconductor: open software development for computational biology and bioinformatics.** *Genome Biol.* 2004; **5**(10): R80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Ritchie ME, Phipson B, Wu D, *et al.*: **limma powers differential expression analyses for RNA-sequencing and microarray studies.** *Nucleic Acids Res.* 2015; **43**(7): e47.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Gray KA, Yates B, Seal RL, *et al.*: **Genenames.org: the HGNC resources in 2015.** *Nucleic Acids Res.* 2015; **43**(Database issue): D1079–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Subramanian A, Tamayo P, Mootha VK, *et al.*: **Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.** *Proc Natl Acad Sci U S A.* 2005; **102**(43): 15545–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Bardou P, Mariette J, Escudie F, *et al.*: **jvenn: an interactive Venn diagram viewer.** *BMC Bioinformatics.* 2014; **15**: 293.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Yamamoto K, Yoshida H, Kokame K, *et al.*: **Differential contributions of ATF6 and XBP₁ to the activation of endoplasmic reticulum stress-responsive cis-acting elements ERSE, UPRE and ERSE-II.** *J Biochem.* 2004; **136**(3): 343–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Dreos R, Ambrosini G, Perier RC, *et al.*: **The Eukaryotic Promoter Database: expansion of EPDnew and new promoter analysis tools.** *Nucleic Acids Res.* 2015; **43**(Database issue): D92–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Thomas-Chollier M, Defrance M, Medina-Rivera A, *et al.*: **RSAT 2011: regulatory sequence analysis tools.** *Nucleic Acids Res.* 2011; **39**(Web Server issue): W86–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Maere S, Heymans K, Kuiper M: **BINGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks.** *Bioinformatics.* 2005; **21**(16): 3448–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Shannon P, Markiel A, Ozier O, *et al.*: **Cytoscape: a software environment for integrated models of biomolecular interaction networks.** *Genome Res.* 2003; **13**(11): 2498–504.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Liberzon A: **A description of the Molecular Signatures Database (MSigDB) Web site.** *Methods Mol Biol.* 2014; **1150**: 153–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Hochberg Y, Benjamini Y: **More powerful procedures for multiple significance testing.** *Stat Med.* 1990; **9**(7): 811–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Hollien J, Weissman JS: **Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response.** *Science.* 2006; **313**(5783): 104–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Arensdorf AM, Diedrichs D, Rutkowski DT: **Regulation of the transcriptome by ER stress: non-canonical mechanisms and physiological consequences.** *Front Genet.* 2013; **4**: 256.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Kaufman RJ: **Orchestrating the unfolded protein response in health and disease.** *J Clin Invest.* 2002; **110**(10): 1389–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Pahl HL: **Signal transduction from the endoplasmic reticulum to the cell nucleus.** *Physiol Rev.* 1999; **79**(3): 683–701.
[PubMed Abstract](#)
55. Friedlander R, Jarosch E, Urban J, *et al.*: **A regulatory link between ER-associated protein degradation and the unfolded-protein response.** *Nat Cell Biol.* 2000; **2**(7): 379–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Kalathur RK, Kamesh A, Futschik ME: **The Unfolded Protein Response and its potential role in Huntington's disease.** *naturepreceedings.* 2012.
[Publisher Full Text](#)
57. Moller T: **Neuroinflammation in Huntington's disease.** *J Neural Transm.* 2010; **117**(8): 1001–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Silvestroni A, Faull RL, Strand AD, *et al.*: **Distinct neuroinflammatory profile in post-mortem human Huntington's disease.** *Neuroreport.* 2009; **20**(12): 1098–103.
[PubMed Abstract](#) | [Publisher Full Text](#)

59. Dalrymple A, Wild EJ, Joubert R, *et al.*: **Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates.** *J Proteome Res.* 2007; **6**(7): 2833–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Singhrao SK, Neal JW, Morgan BP, *et al.*: **Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease.** *Exp Neurol.* 1999; **159**(2): 362–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Sapp E, Kegel KB, Aronin N, *et al.*: **Early and progressive accumulation of reactive microglia in the Huntington disease brain.** *J Neuropathol Exp Neurol.* 2001; **60**(2): 161–72.
[PubMed Abstract](#)
62. Tai YF, Pavese N, Gerhard A, *et al.*: **Microglial activation in presymptomatic Huntington's disease gene carriers.** *Brain.* 2007; **130**(Pt 7): 1759–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
63. Pavese N, Gerhard A, Tai YF, *et al.*: **Microglial activation correlates with severity in Huntington disease: a clinical and PET study.** *Neurology.* 2006; **66**(11): 1638–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Farrer LA: **Diabetes mellitus in Huntington disease.** *Clin Genet.* 1985; **27**(1): 62–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Podolsky S, Leopold NA: **Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease.** *Gerontology.* 1977; **23**(1): 55–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Hurlbert MS, Zhou W, Wasmeier C, *et al.*: **Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes.** *Diabetes.* 1999; **48**(3): 649–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Jenkins BG, Klivenyi P, Kustermann E, *et al.*: **Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice.** *J Neurochem.* 2000; **74**(5): 2108–19.
[PubMed Abstract](#) | [Publisher Full Text](#)
68. Andreassen OA, Dedeoglu A, Stanojevic V, *et al.*: **Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression.** *Neurobiol Dis.* 2002; **11**(3): 410–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
69. Stroedicke M, Bounab Y, Stempel N, *et al.*: **Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity.** *Genome Res.* 2015.
70. Tam S, Geller R, Spiess C, *et al.*: **The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions.** *Nat Cell Biol.* 2006; **8**(10): 1155–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Lotz GP, Legleiter J, Aron R, *et al.*: **Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle.** *J Biol Chem.* 2010; **285**(49): 38183–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
72. Min HJ, Ko EA, Wu J, *et al.*: **Chaperone-like activity of high-mobility group box 1 protein and its role in reducing the formation of polyglutamine aggregates.** *J Immunol.* 2013; **190**(4): 1797–806.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
73. Nishitoh H, Matsuzawa A, Tobiume K, *et al.*: **ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats.** *Genes Dev.* 2002; **16**(11): 1345–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
74. Schmid JA, Birbach A: **IkkappaB kinase beta (IKKbeta/IKK_β/IKKB_β)—a key molecule in signaling to the transcription factor NF-kappaB.** *Cytokine Growth Factor Rev.* 2008; **19**(2): 157–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
75. Frelin C, Imbert V, Griessinger E, *et al.*: **Targeting NF-kappaB activation via pharmacologic inhibition of IKK2—induced apoptosis of human acute myeloid leukemia cells.** *Blood.* 2005; **105**(2): 804–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Khoshnan A, Ko J, Tesco S, *et al.*: **IKKalpha and IKKbeta regulation of DNA damage-induced cleavage of huntingtin.** *PLoS One.* 2009; **4**(6): e5768.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
77. Muller-Rischart AK, Pils A, Beaudette P, *et al.*: **The E3 ligase parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO.** *Mol Cell.* 2013; **49**(5): 908–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
78. Jensen LT, Moller TH, Larsen SA, *et al.*: **A new role for laminins as modulators of protein toxicity in *Caenorhabditis elegans*.** *Aging Cell.* 2012; **11**(1): 82–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
79. Heng MY, Lin ST, Verret L, *et al.*: **Lamin B1 mediates cell-autonomous neuropathology in a leukodystrophy mouse model.** *J Clin Invest.* 2013; **123**(6): 2719–29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
80. Padiath QS, Saigoh K, Schiffmann R, *et al.*: **Lamin B1 duplications cause autosomal dominant leukodystrophy.** *Nat Genet.* 2006; **38**(10): 1114–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
81. Giorgio E, Robyr D, Spielmann M, *et al.*: **A large genomic deletion leads to enhancer adoption by the lamin B1 gene: a second path to autosomal dominant adult-onset demyelinating leukodystrophy (ADLD).** *Hum Mol Genet.* 2015; pii: ddv065.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. Rue L, Alcalá-Vida R, López-Soo G, *et al.*: **Early down-regulation of PKC δ as a pro-survival mechanism in Huntington's disease.** *Neuromolecular Med.* 2014; **16**(1): 25–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
83. Naora H, Takai I, Adachi M: **Altered cellular responses by varying expression of a ribosomal protein gene: sequential coordination of enhancement and suppression of ribosomal protein S3a gene expression induces apoptosis.** *J Cell Biol.* 1998; **141**(3): 741–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. Grupe A, Li Y, Rowland C, *et al.*: **A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease.** *Am J Hum Genet.* 2006; **78**(1): 78–88.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
85. De Graeve S, Marinelli S, Stolz F, *et al.*: **Mammalian ribosomal and chaperone protein RPS3A counteracts α -synuclein aggregation and toxicity in a yeast model system.** *Biochem J.* 2013; **455**(3): 295–306.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
86. Kim I, Xu W, Reed JC: **Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities.** *Nat Rev Drug Discov.* 2008; **7**(12): 1013–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
87. Kalathur R, Giner-Lamia J, Machado S, *et al.*: **Raw data for Kalathur *et al.*, 2015 'The unfolded protein response and its potential role in Huntington's disease elucidated by a systems biology approach' Figshare.** 2015.
[Data Source](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 05 August 2015

<https://doi.org/10.5256/f1000research.6818.r9517>

© 2015 Taubert S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Stefan Taubert

Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada

In this paper, Kalathur *et al.* investigated the role of the ER's unfolded protein response (UPR) in the disease pathogenesis of Huntington's Disease (HD). Although HTT, the protein mutated in HD, does not localize to the ER, mutated HTT interferes with downstream UPR processes, which may prevent the UPR from functioning normally and thus result in the induction of apoptosis by the UPR, which in turn could underlie the dramatic neuronal loss observed in HD. To broadly evaluate the role of UPR activation in the many experimental HD models and contexts, the authors used a bioinformatics approach to query for the role of the UPR in HD pathology, assessing transcriptomes, regulatory DNA elements, and UPR interactomes. The resulting data point to a core set of UPR genes that were commonly (although, as nicely pointed out, not universally) up- or downregulated in distinct experimental HD models, pro-inflammatory events involving microglia, a putative link between HD and diabetes/hyperglycemia, and the identification of a core set of genes that link UPR to apoptotic signaling and that mHTT may impinge upon.

Overall, this is a nice body of work. This computational analysis is comprehensive and multifaceted, the data interpretation measured and well-qualified, the paper well written, and the data are very accessible. One of the key strengths is that the authors aimed to integrate data obtained in many different experimental HD systems - various mouse models, human data, and even yeast and rat models. This comprehensive approach allows them to point to evolutionarily conserved genes and processes as suitable candidates for future investigation.

Specific criticism:

- To derive their set of HTT interacting proteins, the authors use a dataset downloaded from HDNetDB database, which yields a large set of HTT interactors (HTT-int) including 1015 genes, including, as acknowledged, presumably many indirect interactors. Perhaps a deeper up-front curation for putative direct interactors would have been useful.
- In Figure 2, the authors assess the overlap between genes regulated in 6 mouse HD datasets and one human HD. To ensure best stringency, the first limit the mouse dataset to those genes that are regulated in all 6 individual datasets. While this high stringency is

laudable, one could have also lowered the stringency a bit in regards to inclusion in the core mouse IPR set, i.e. inclusion in 6/6 sets was deemed required, but expanding the set to 5/6 or even 4/6, resulting in 420 and 902 additional genes, respectively, would have only marginally lowered the stringency while providing a larger set for the determination of evolutionary conservation.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 17 Feb 2016

Ravi Kiran Reddy Kalathur, Centre for Biomedical Research, University of Algarve, Portugal

We thank the reviewer for the positive comments and specific suggestions that helped us to further improve our manuscript. In the revised version, we have included the additional analysis suggest by the reviewer.

1. We distinguish now between direct and indirect interactions of HTT based on their annotation in HDNetDB. An additional supplementary table (Supplementary dataset 8) presents now the classification of HTT interactions. This information was also used for the interpretation of our results. For instance, 2 of the 13 proteins constituting a putative link between HD and UPR, were direct interactors. We did not want to exclude a priori all indirect HTT interactors, since those might be part of larger protein complexes with HTT and thus potentially important for the HTT's molecular functions.
2. Additional lists of genes with evolutionary conserved expression were generated for less stringent filters (i.e. requiring the inclusion in the enrichment cores of at least 5 or 4 comparisons for up- or downregulated genes, respectively). In general, promotor and enrichment analyses of the extended gene lists agree well with those for the more stringent genes lists. The results are presented in supplementary tables and figures, and briefly discussed in the main manuscript. For the connection to HD, lowering the requirement led to detection of 53 candidates, of which 15 were direct HTT interactors (Supplementary figure 5). This enlarged set is presented in Supplementary dataset 9 for the interested reader.

Competing Interests: No competing interests were disclosed.

Reviewer Report 29 July 2015

<https://doi.org/10.5256/f1000research.6818.r9713>

© 2015 Zeitlin S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Scott Zeitlin

Department of Neuroscience, School of Medicine, University of Virginia, Charlottesville, VA, USA

In HD and other neurodegenerative disorders involving the accumulation of misfolded protein, ER stress and the activation of UPR have been implicated in pathogenesis, although the extent to which it contributes to neuronal cell death is still unclear. In this paper, the authors employ a bioinformatic approach to show that the unfolded protein response (UPR) is activated in a variety of human and animal Huntington's disease (HD) models. It is noteworthy that the authors also demonstrate that the upregulation of the UPR genes is most likely a direct response to UPR activation by analyzing the promoter regions of these genes for the binding sites of the UPR transcriptional activators ATF6 and XBP1. Moreover, the authors also identified sets of genes that provide a potential link between both UPR and HD and between UPR and apoptosis. Pathway enrichment analysis was also used to identify functional pathways activated by the common set of upregulated UPR genes. In addition to the expected pathways associated with UPR (e.g. PERK-regulated gene expression and ATF-activated genes), the authors also identified components of the immune system, neurotrophin signaling, and diabetes. Interestingly, there is evidence in the HD literature that all three of these latter pathways are affected in HD.

This work is a good example of the power of using a systems biology approach to provide a fairly comprehensive analysis of UPR activation in HD. The authors are appropriately cautious in emphasizing that their results do not prove that the pathways and relationships between pathways that they have identified all contribute to HD pathogenesis. However, their results provide an excellent guide for further experimental studies, and the authors' development of a publicly accessible web site for the retrieval and visualization of their UPR-associated gene expression data in HD will be an important tool for the field that will facilitate these future studies.

Minor comments:

1. In the introduction, the authors mention that although HTT is not located in the ER, there are several potential mechanisms by which mutant HTT could induce ER stress (impairment of ERAD, dysfunctional vesicular trafficking, and altered ER calcium homeostasis). [Atwal et al., \(2007\)](#) and [Atwal and Truant \(2008\)](#) have shown that there is a more direct link between HTT and ER stress. In their work, they show that the N17 domain of HTT is a stress-sensitive ER association domain, and that the expanded polyQ stretch in mutant HTT perturbs the release of mutant HTT from ER and its translocation of HTT into and out of the nucleus in response to cell stress events.
2. p.7, 1st paragraph: "...UPR has been also associated with the suppression or degradation of a substantial number of genes.... Do the authors mean: ...UPR has been also associated with the suppression or degradation of a substantial number of genes or gene products?
3. To account for the differences in differential UPR gene expression changes that were observed among the different HD mouse models, the authors suggest that differences in the *HTT* transgenes and their expression levels among the models could be responsible. In addition, the different genetic backgrounds of the models can contribute to the variability. In future studies aimed at studying the role of the length of mutant HTT's expanded polyQ stretch in UPR activation, the authors may also want to consider evaluating CHDI's publicly available transcriptome data obtained from the cortex and striatum of 6-month old knock-in HD mouse models expressing wild-type or mutant *Htt* alleles with different CAG repeat

lengths.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 17 Feb 2016

Ravi Kiran Reddy Kalathur, Centre for Biomedical Research, University of Algarve, Portugal

We would like to thank the reviewer for the encouraging evaluating of our systems biology approach and his suggestions for further improvement of the study and its presentation. In response to the comments, following changes to the manuscript were made:

1. In the Introduction, we pointed out the finding of a stress-sensitive association of HTT with the ER membrane, which suggests a potential direct role of HTT in ER stress. The relevant references are now included.
2. We clarified the meaning of the sentence. It states now: "As the UPR has also been associated with suppression of gene transcription and the enhanced degradation of numerous transcripts, ..."
3. We would like to thank reviewer for pointing out this data set. We analysed the correlation of expression changes with the length of polyglutamine tract. Notably, UPR genes were found to be strongly overrepresented among genes whose expression in the striatum significantly correlate with the length of polyglutamine tract. The correlation and the corresponding significance are also shown for the potential UPR-HD connectors in table 3 and Supplementary dataset 9. The results suggest length of the polyglutamine tract (which is reversely correlated with age of disease onset in human patients) plays a critical role in the activation of UPR. We aim to include these expression changes also in our newly developed web-portal UPRHD at <http://uprhd.sysbiolab.eu>.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research